BMS Archive

Fungi · Scientific monograph

Ganoderma lucidum

Reishi / Lingzhi

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Immunological Research, Cellular & Immune Studies, Stress Response Research

Research overview

Historical use

Known in Traditional Chinese Medicine for over 2,000 years as 'Lingzhi' (spirit mushroom), revered as the 'mushroom of immortality'. Used by Taoist monks to promote longevity, calm the mind, and nourish the heart. Referenced in the Shen Nong Ben Cao Jing (c. 100 CE) as a superior tonic.

Modern research context

Clinically studied as an adjunct in oncology for immunomodulation — trials show increased NK cell and T-lymphocyte activity [1]. Hepatoprotective and anti-fatigue properties documented in preclinical and clinical contexts [1]. Beta-glucan polysaccharides demonstrate anti-proliferative activity against multiple cancer cell lines in vitro [2]. Gut microbiome modulation has been documented in murine models [3]. Anti-cancer potential in breast and colorectal cancer is supported by in vitro and network pharmacology studies [4][5].

Adverse effects

GI upset (nausea, diarrhoea), dry mouth, dizziness, and skin rash with prolonged use (>3–6 months). Rare but documented cases of hepatotoxicity, predominantly associated with powdered (not extract) preparations. Potential for increased bleeding time.

Contraindications

Contraindicated with anticoagulants (warfarin, heparin) and antiplatelet drugs due to platelet aggregation inhibition. Use with caution alongside immunosuppressants and chemotherapy agents. Avoid prior to surgery.

Clinical and phytochemical data

Used part

Fruiting body and mycelium

Primary active compounds

  • Ganoderic acids (triterpenoids)

  • Beta-1,3/1,6-D-glucans

  • Polysaccharides (GL-PS)

  • Lucidenic acids

  • Ganoderiol

Mechanism of action

Immunomodulation via activation of NK cells, macrophages, and dendritic cells through TLR-4/NF-κB signalling. Ganoderic acids inhibit HMG-CoA reductase (cholesterol synthesis), suppress NF-κB transcription, and induce tumour cell apoptosis via the intrinsic mitochondrial pathway. Antioxidant activity via Nrf2/HO-1 upregulation.

Pharmacokinetics

Absorption

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Preclinical oral bioavailability data for Ganoderma polysaccharides reviewed in Ye D et al. (2023), Int J Biol Macromol (PMID 37625759). Polysaccharides show low oral bioavailability; ganoderic acids are absorbed but undergo significant first-pass metabolism. Bioavailability data from human PK studies is limited.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Ganoderic acids are highly lipophilic and distribute preferentially into the liver, adipose tissue, and kidneys. Plasma protein binding of triterpenoids exceeds 90%. Polysaccharide fractions concentrate at gut-associated lymphoid tissue (GALT) and spleen. No quantitative human tissue distribution data are available.

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Animal pharmacokinetic data for ganoderic acids available in Zhang FF et al. (2019), Zhongguo Zhong Yao Za Zhi (PMID 30989848). Hepatic; ganoderic acids are substrates of CYP3A4. Triterpenoids undergo glucuronidation and sulfation.

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Primarily biliary (feces) for polysaccharides; renal excretion for water-soluble metabolites.

Safety and interactions

Drug interactions

Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.

Toxicity

LD50 >5 g/kg in mice (oral). Chronic use at high doses associated with rare hepatotoxicity (elevated ALT/AST); reversible upon discontinuation.

Special precautions

Pregnancy

Insufficient human safety data. Animal studies show no teratogenicity at low doses, but high-dose use is not recommended. Avoid during first trimester.

Lactation

Excretion in human breast milk unknown. Avoid due to insufficient safety data.

Hepatic impairment

Use with caution. Rare hepatotoxicity reported; baseline and periodic liver enzyme monitoring recommended in patients with pre-existing hepatic disease.

Renal impairment

Limited specific data. No established contraindication at standard doses; dose reduction may be prudent in severe renal impairment.

Sources and references

  1. [1] - Ahmad R., "Ganoderma lucidum (Reishi) an edible mushroom; a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties.", Phytother Res, 2021, PMID: 34411377
  2. [2] - Sohretoglu D., "Ganoderma lucidum Polysaccharides as An Anti-cancer Agent.", Anticancer Agents Med Chem, 2018, PMID: 29141563
  3. [3] - Chang CJ., "Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota.", Nat Commun, 2015, PMID: 26102296
  4. [4] - Gariboldi MB., "Anti-Cancer Potential of Edible/Medicinal Mushrooms in Breast Cancer.", Int J Mol Sci, 2023, PMID: 37373268
  5. [5] - Zhao X., "Network Pharmacology and Bioinformatics Study of Six Medicinal Food Homologous Plants Against Colorectal Cancer.", Int J Mol Sci, 2025, PMID: 39940699

Additional source links

Continue browsing